FDA approves larger dose of Pfizer's Aricept

(AP) -- Drugmakers Eisai Inc. and Pfizer Inc. said on Saturday that government regulators have given them permission to make a larger dose of its Alzheimer's disease drug Aricept for patients who have already been taking the smaller dose.

Aricept is the version of the drug donepezil, and is co-marketed by Eisai, of Japan, and Pfizer. Its 2009 revenue for was $432 million, with another $3.3 billion for Eisai, making it the largest seller out of four drugs that can temporarily reduce Alzheimer's symptoms.

The companies said the higher dose improved scores on a patient test that measures cognition. There was no difference on a different test that measures global function.

Approval by the followed a study of 1,467 patients with moderate to severe Alzheimer's. It said the larger dose is recommended for patients who are already taking smaller doses daily for at least three months.


Explore further

Pfizer drug found with serious side effect

©2010 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Citation: FDA approves larger dose of Pfizer's Aricept (2010, July 25) retrieved 12 December 2019 from https://medicalxpress.com/news/2010-07-fda-larger-dose-pfizer-aricept.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments